English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT02625961 /

MK-3475-057

A Phase II Clinical Trial To Study The Efficacy And Safety Of Pembrolizumab (MK-3475) In Subjects With High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive To Bacillus Calmette-Guerin (BCG) Therapy

DISEASE GROUP:
Genito-Urinary
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: